An interventional study of deferiprone and placebo in Parkinson's Disease, Amyotrophic Lateral Sclerosis and Oxidative Stress, sponsored by University Hospital, Lille. Completed at 1 site in France. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-14.
Sponsored by University Hospital, Lille · Not applicable, Interventional, and Basic science
Peripheral blood mononuclear cells (PBMC) and platelets could be interesting ex vivo models to study brain diseases. Indeed, there is no access to neurons from patients. However, PBMC can exhibit different physiopathological mechanisms that are ubiquitous (i.e. oxidative stress, mitochondriopathy with energy metabolism, inflammation, protein folding, iron metabolism and programmed cell death ...). The platelets are pivotal in the healing system with large range of growth factors. A new therapeutic concept of conservative iron chelation with deferiprone for neuroprotection is under development.
The action of deferiprone on the different mechanisms and notably the oxidative stress are to obtain from a collection of PBMC and platelets from patient having Parkinson's disease and Amyotrophic lateral sclerosis and healthy controls to study ex vivo.
PBMC and platelets will be stored for future analyses.
The study collection of PBMC and platelets from 30 patient having Parkinson's disease 30 patients having Amyotrophic lateral sclerosis and 30 healthy controls.
The collection will be performed either by cytapheresis for half of the patient and by collecting the whole blood for the other half.
PBMC and platelets will be stored at minus 80°C. PBMC of patients and controls are exposed ex vivo to different pathological condition (mainly Hydrogen peroxide, menadione, hypoxia...) with and without deferiprone to analyse whether the level of oxidative stress (Reactive Oxygen Species and notably hydroxyl radical with hydroxypethidine probe with flow cytometry) is reduced under deferiprone (primary criterion. Secondary analyses will concern the level of iron, the energy metabolism (aerobic versus anaerobic and the level of Adenosine triphosphate production), the type of cell death (apoptosis, autophagy and new programmed cell death: Ferroptosis) and inflammation. Finally, the level of growth factors and their effectiveness will be studied from platelets.
4,573 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
This study's enrollment of 90 is above the median of 40 across 3,353 interventional studies indexed under Parkinson Disease.
Browse Parkinson Disease studies →University Hospital, Lille is the lead sponsor of 631 studies on the registry; 142 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
ex vivo analysis of lymphocytes from 30 patients with Parkinson's disease with deferiprone and placebo treatment
Drug: deferiprone · Drug: placebo
ex vivo analysis of lymphocytes from 30 patients with Amyotrophic lateral sclerosis with deferiprone and placebo treatment
Drug: deferiprone · Drug: placebo
ex vivo analysis of lymphocytes from 30 healthy age and sex matched controls with deferiprone and placebo treatment
Drug: deferiprone · Drug: placebo
to test the action of deferiprone on lymphocytes from patients and controls ex vivo
Also known as: FERRIPROX
to control the action of placebo on lymphocytes from patients and controls ex vivo
hydroxyl radical measured
hydroxypethidine probe with Fluorescence-activated cell sorting
Time frame: 12 months
adenosine triphosphate production measured by seahorse
seahorse experimentation
Time frame: 12 months
oxygen consumption measured by seahorse
seahorse experimentation
Time frame: 12 months
free reactive iron (ferrous iron)
calceine assay
Time frame: 12 months
lipid peroxidation measured by Fluorescence-activated cell sorting
flow cytometry with bodipy probe
Time frame: 12 months
Plan to share: No
The record gives a start of Feb 2011, a primary completion of Oct 2019 and a completion of Mar 2020. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Deferiprone